Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 5.25
High: 5.25
Low: 5.00
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Cohort trading ahead of expectations, record orders

Tue, 26th Sep 2023 19:38

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Cohort PLC - Reading, England-based defence and security technology firm - Updates on first quarter trading ahead of annual general meeting. Achieved record financial results in the year ended April 30, with strong performances in revenue and adjusted operating profit that exceeded market expectations. "We finished the year with a robust cash position and a record closing order book of GBP329.1 million stretching out to 2032, with strong revenue cover for the current financial year," firm adds. Explains following contract wins since the start of the financial year of over GBP90 million, the order book on September 22 stood at GBP370 million, representing consensus revenue cover for the current financial year of 93%. Retains significant cash and banking facilities to fund its currently anticipated commitments and, potentially, to finance future acquisitions. As a result of planned capital expenditure and expansion in working capital, anticipates net cash balance will decrease, but that it will maintain positive net funds at the year end. States expectations for the full year remain unchanged.

----------

Beowulf Mining PLC - Sweden, Finland and Kosovo-focused mining company -Updates on the development plans for the graphite anode materials plant in GigaVaasa. Plans to advance parallel environmental and technical work streams for the development of the GAMP. Says the environmental impact assessment is underway and is expected to be completed in the first quarter of 2024. On completion and submission of the EIA, explains the company will initiate work on the environmental permit process. Anticipates that the definitive feasibility study will begin in mid-2024.

----------

Sabien Technology Group PLC - London-based company focused on green technologies such as plastic-to-oil recycling and CO2 mitigation for commercial and residential boilers - Reviews the value of its investment in Proton Technologies Canada Inc, following the proposed investment in and restructuring of Proton. Concludes that the value of the stake, which is GBP100,000, may require a material impairment provision for the financial year to June 30. Says the level of provision will require agreement with the company's auditors as part of the current audit process.

----------

Eqtec PLC - thermochemical conversion technology and engineering company - Says Eqtec France SAS have completed a technical and commercial feasibility toward deployment of Eqtec solutions at the site of the former Gardanne power station. Completion of the feasibility represents a critical step toward commencement of development and design work on what is expected to be a waste-to-renewable natural gas facility enabled by Eqtec's advanced syngas technology. Expects initial front-end engineering design work to commence in the coming weeks, for which it expects to bill around EUR250,000 for engineering services. Anticipates that it would lead full, front-end engineering design work, estimated to be worth at least EUR750,000 in fees, with the majority to be invoiced over the first half of 2024.

----------

Driver Group PLC - Lancashire, England-based professional services consultancy to construction and engineering industries - Announces a trading update for the year ending September 30. Notes, as indicated in June, the start of the second half was slower than expected. Adds the third quarter experienced reductions in the levels of activity, with an improvement seen in the fourth quarter and a number of significant commissions secured in this period which will benefit the financial year. Expects underlying pretax profit in the financial year compared to a pretax loss of GBP1.0m in the year prior. Also expects to report an improvement in the September 2023 year end cash position from GBP5.3 million in March. Progress has been made on cost reductions including the closure of overseas offices, reduction of existing office lease costs and adjustments to headcount in several locations.

----------

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Announces the completion of dosing of healthy volunteers in the first two cohorts in the Phase I Protect trial of its virus-like particle-based peanut allergy vaccine candidate. Explains dosing of the subsequent cohorts will begin now that the approval from the external safety review committee has been received. Further, says the safety review committee has approved the commencement of subcutaneous dose escalation in peanut allergic subjects, marking the start of the early proof of concept phase of the Protect trial. This stage of the trial is expected to begin imminently with the full results expected in 2024.

----------

DWF Group PLC - Manchester, England-based legal business with operations in North America - Announces that all of the conditions to the acquisition by Inflexion Private Equity Partners relating to anti-trust and regulatory approvals have been received. Explains the deal remains subject to certain other conditions including the court sanctioning the scheme at the sanction hearing. Subject to satisfaction of these conditions, the scheme is expected to become effective on October 3. Confirms that the sanction hearing will go ahead as scheduled on September 29.

----------

CleanTech Lithium PLC - Chile-focused lithium exploration and development company - Announces results of a recently completed scoping study for the Francisco Basin project. Says these confirm the project's outstanding economics, potential for future resource expansion and strong ESG credentials. Notes this supports the potential for Francisco Basin to become a major supplier of battery grade lithium to European and US markets based on sustainable direct lithium extraction technology. Forecasts a production period of 12 years based on annual production of 20,000 tonnes given Indicated resources. Calculates accumulated net cash flows of USD2.5 billion to be generated over the production period with low operating cost of USD3,641 per tonne of lithium carbonate.

----------

HealthBeacon PLC - Dublin-based devices and software developer for managing critical and chronic medications -

Reports progress with the roll-out of its technology across key channels. However, the scale and complexity of implementations, and the contracting and planning phases of new launches, are running up to 9 months longer than previously estimated. Cautions annual recurring revenue guidance for December 2023 is around EUR3.2 million versus previous estimates of mid-teens by the end of 2023. Revises ARR guidance to approximately EUR17 million by the end of the fourth quarter. To accelerate its path to profitability and improve cash management company plans reduce monthly cash burn to around EUR0.7 million by the end of 2023 and is currently expected to result in cash break even being achieved by the second quarter 2025. To achieve cash break even and scale at the pace now expected, the company has a gross funding requirement of approximately EUR11 million over the next 18-24 months. Therefore, initiates review of funding options to provide the required resources to deliver the forecasted growth into 2024.

Further, says Chief Executive and Co-Founder Jim Joyce is to step down from his role with immediate effect. Joyce will remain as an adviser to the board, and a non-executive director. Rebecca Shanahan, an independent non-executive director, will assume the role of chief executive on an interim basis.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
20 Jan 2023 10:37

Allergy Therapeutics revenue drops but optimistic about funding

(Alliance News) - Allergy Therapeutics PLC on Friday said it expects a drop in revenue during the first half of its financial year, but it remains confident about funding opportunities.

Read more
29 Dec 2022 16:52

LONDON MARKET CLOSE: FTSE 100 edges higher and New York stocks jump

(Alliance News) - London's FTSE 100 achieved a solid, though unspectacular, gain during the final full trading of the year on Thursday, with investors mindful of what an ease of Covid-19 curbs in China could mean for global inflation.

Read more
29 Dec 2022 12:14

LONDON MARKET MIDDAY: Covid concerns in China drag stocks lower

(Alliance News) - Stock prices in London at midday continued to be weighed down by the worrying surge in Covid-19 cases as China swiftly re-opens from three years of strict lockdown measures.

Read more
29 Dec 2022 09:26

AIM WINNERS & LOSERS: Allergy Therapeutics plunges as results delayed

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
29 Dec 2022 08:50

LONDON MARKET OPEN: Sea of red as investors fret over Covid in China

(Alliance News) - Stock prices in London opened lower on Thursday amid risk-off sentiment across Europe, as concerns grew about rising Covid cases in China.

Read more
29 Dec 2022 08:22

Allergy Therapeutics shares halve as delayed audit to mean suspension

Alliance News) - Allergy Therapeutics PLC on Thursday said it shares will be suspended next week, due to delays in completing the audit of its annual results.

Read more
8 Dec 2022 11:07

AIM WINNERS & LOSERS: Redcentric boasts "transformational" half-year

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
8 Dec 2022 11:04

Allergy Therapeutics proffers peanut progress despite cost concerns

(Alliance News) - Allergy Therapeutics PLC on Thursday saw shares drop despite the start of its peanut allergy testing trial, after it confirmed that cost control remains a preoccupation for management following a pause in production earlier in the year.

Read more
21 Nov 2022 17:00

Allergy Therapeutics hires interim CFO as Nick Wykeman steps down

(Alliance News) - Allergy Therapeutics PLC on Monday said it appointed Martin Hopcroft as interim chief financial officer, as Nick Wykeman will step down at the end of November.

Read more
28 Oct 2022 11:33

AIM WINNERS & LOSERS: Directa Plus wins deal; Greatland loss widens

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
28 Oct 2022 11:10

IN BRIEF: Allergy Therapeutics resumes output; warns on revenue miss

Allergy Therapeutics PLC - West Sussex-based commercial biotechnology company - Says it will resume production at Freeman facility in Worthing, UK on November 14. This follows a short-term voluntary pause as it reviewed its operating processes. Says the pause was planned, to help improve "robustness" of quality systems and build capacity. It was then accelerated when the firm realised capacity could not cope with commercial demand. "The pause in manufacturing occurred during a period of peak production prior to the start of the pollen season in the spring," it says. Consequently, it estimates revenue will be around 13% to 18% lower than market expectations of around GBP80 million, for the year to June 30.

Read more
17 Oct 2022 16:31

TRADING UPDATES: IQE, Trellus Health and Insig sign new agreements

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
4 Oct 2022 14:10

Allergy Therapeutics pauses production at Freeman facility

(Sharecast News) - Biotechnology company Allergy Therapeutics has "proactively paused" production at the Freeman facility, part of its Worthing manufacturing site, to accelerate ongoing site improvements, it announced on Tuesday.

Read more
4 Oct 2022 11:19

AIM WINNERS & LOSERS: N4's Nuvec success; Watkin Jones tumbles

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
4 Oct 2022 10:35

Allergy Therapeutics shares down as pauses production at UK facility

(Alliance News) - Allergy Therapeutics PLC shares dropped on Tuesday following production at the Freeman facility, part of its Worthing, UK manufacturing site, being paused.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.